Histiocitosis de células mixtas: reporte de un caso

Verónica Ullauri-Zambrano; Damary S.  Jaramillo-Aguilar; Medardo David  Salinas-Herrera; Leslie M.  Suntaxi-Basantes

doi:10.35434/rcmhnaaa.2022.153.1102

Authors

Verónica Ullauri-Zambrano Hospital de Especialidades “José Carrasco Arteaga” (IESS), Cuenca, Ecuador; Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.
Damary S. Jaramillo-Aguilar Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.
Medardo David Salinas-Herrera Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.
Leslie M. Suntaxi-Basantes Escuela de Medicina, Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.

DOI:

https://doi.org/10.35434/rcmhnaaa.2022.153.1102

Keywords:

Histiocytosis, Histiocytosis, Langerhans-Cell, Histiocytosis, Non-Langerhans-Cell, Ecuador, Hematology

Abstract

Introduction: Histiocytoses are rare diseases characterized by tissue infiltration by abnormal histiocytes. They are divided into five groups. They are frequent in the pediatric population. The combination of Langerhans cell histiocytosis and non-Langerhans cell histiocytosis is fortuitous. Case report: We report the case of a 66-year-old female patient who debuted with a history of systemic involvement, in which the presence of tumor masses on the anterior aspect of the legs, generalized bone pain and endocrinological alterations attracted our attention. The diagnosis of mixed histiocytosis was suggested. Treatment with anti BRAF V600E monoclonal antibodies, interferon alpha and/or chemotherapy was recommended. Conclusion: It is possible to make the diagnosis of histiocytosis based on the patient's personal pathological history and the clinical findings with the support of radiological, histological and immunohistochemical studies. Finally, this is the first case of mixed histiocytosis published in Ecuador.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Verónica Ullauri-Zambrano , Hospital de Especialidades “José Carrasco Arteaga” (IESS), Cuenca, Ecuador; Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.

Médico Especialista en Hematología. Docente de la Cátedra de Hematología

Damary S. Jaramillo-Aguilar , Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.

Médico General

Medardo David Salinas-Herrera , Escuela de Medicina, Facultad de Ciencias Médicas, Universidad de Cuenca, Cuenca, Ecuador.

Médico Interno del Pregrado de Medicina.

Leslie M. Suntaxi-Basantes , Escuela de Medicina, Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.

Médico Interno del Pregrado de Medicina.

References

Vaglio A, Rocco R, Haroche J, Emile J-F. Histiocytosis. In: G. Ragab et al., editor. The Microbiome in Rheumatic Diseases and Infection. Parma, Italy: Springer International Publishing AG; 2018. p. 379–90. doi: 10.1007/978-3-319-79026-8.

Serra-García L, Morgado-Carrasco D. Cutaneous manifestations of histiocytoses. Piel. 2020;(November):1–10. doi: 10.1016/j.piel.2020.05.013.

Emile J-F, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–81. doi: 10.1182/blood-2016-01-690636.

Villaseñor EM, Mckinster CD, Covarrubias LO, López CP, Sáez-de-Ocáriz M, García MT. Langerhans Cell Histiocytosis: New Molecular and Clinical Concepts. Dermatología CMQ [Internet]. 2018 [citado el 16 de abril de 2021];16(1):36–44. Disponible en: https://bit.ly/3iBBLZ0.

Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483. doi: 10.1182/blood-2014-03-561381.

Sterlich K, Minkov M. Childhood Langerhans Cell Histiocytosis: Epidemiology, Clinical Presentations, Prognostic Factors, and Therapeutic Approaches. In: Rare Diseases. InTechOpen; 2021. p. 1–23. doi: 10.5772/intechopen.96543.

Cueva P, Yépez J. Epidemiología del Cáncer en Quito 2011-2015 [Internet]. 16ª ed. Quito: SOLCA; 2019 [citado el 18 de abril de 2021]. Disponible en: https://bit.ly/3DhMHVQ.

Bonometti A. The triptych of mixed histiocytosis: a systematic review of 105 cases and proposed clinical classification proposed clinical classification. Leuk Lymphoma. 2020;1–13. doi: 10.1080/10428194.2020.1824070.

Hervier B, Haroche J, Arnaud L, Donadieu J, Antoine N, Villabona C, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAF V600E mutation. Blood. 2014;124(7):1119–26. doi: 10.1182/blood-2013-12-543793.

Goyal G, Young JR, Koster MJ, Tobin WO, Vassallo R, Ryu JH, et al. The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients with Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease. Mayo Clin Proc. 2019;94(10):2054–71. doi: 10.1016/j.mayocp.2019.02.023.

Goyal G, Heaney M, Collin M, Cohen-Aubart F, Vaglio A, Durham B, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929–1945. doi: 10.1182/blood.2019003507.